IFNAR1 and plasma cell myeloma: Myeloma-cell-secreted type 1 IFN has been suggested as a mediator of Treg activation and expansion in a syngeneic transplantable murine myeloma model, in which treatment with a blocking IFNAR1 antibody inhibited myeloma progression [193].